Analysis of USRDS: Incidence and Risk Factors for Pneumocystis jiroveci Pneumonia
- 15 July 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 88 (1), 135-141
- https://doi.org/10.1097/tp.0b013e3181aad256
Abstract
Background. To investigate the effect of modern immunosuppression on the incidence, risk factors, morbidity, and mortality of Pneumocystis pneumonia (PCP) in recipients of kidney transplants. Methods. We conducted a retrospective cohort study of 32,757 Medicare primary transplant recipients in the United States Renal Data System from January 1, 2000 through July 31, 2004. PCP infection was defined by Medicare claims using International Classification of Disease, 9th Revision codes. The incidence of PCP infections, graft loss, and death were measured. Results. There were a total of 142 cases (cumulative incidence 0.4%) of PCP after kidney transplantation during the study period. By using multivariate analysis with Cox regression, expanded criteria donor, donation after cardiac death, and earlier year of transplant were associated with development of PCP disease. Induction immunosuppression and acute rejections were not associated with risk for PCP infections. However, based on adjusted hazard ratio (AHR), maintenance immunosuppression regimens containing the combination of tacrolimus and sirolimus (AHR 3.60, confidence interval [CI] 2.03–6.39), Neoral and mycophenolate mofetil (AHR 2.09, CI 1.31–3.31), and sirolimus and mycophenolate mofetil (AHR 2.77, CI 1.40–5.47), were associated with development of PCP. As a time dependent variable, PCP was associated with an increased risk of both graft loss and death. Conclusion. PCP infections are rare in the modern era of prophylaxis; however, these infections are a serious risk factor for graft loss and patient death, in particular, in patients who are on sirolimus as part of the immunosuppressive regimen. The median time to development of PCP after transplant was 0.80±0.95 years, suggesting a longer period of PCP prophylaxis.Keywords
This publication has 14 references indexed in Scilit:
- Pneumocystis jiroveci (formerly Pneumocystis carinii)American Journal of Transplantation, 2004
- Prevention of Infection Due to Pneumocystis spp. in Human Immunodeficiency Virus-Negative Immunocompromised PatientsClinical Microbiology Reviews, 2004
- Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case–control studyTransplant Infectious Disease, 2003
- CONVERSION TO RAPAMYCIN IMMUNOSUPPRESSION IN RENAL TRANSPLANT RECIPIENTS: REPORT OF AN INITIAL EXPERIENCE1Transplantation, 2000
- SIROLIMUS REDUCES THE INCIDENCE OF ACUTE REJECTION EPISODES DESPITE LOWER CYCLOSPORINE DOSES IN CAUCASIAN RECIPIENTS OF MISMATCHED PRIMARY RENAL ALLOGRAFTS: A PHASE II TRIAL1Transplantation, 1999
- Should Prophylaxis for Pneumocystis carinii Pneumonia in Solid Organ Transplant Recipients Ever Be Discontinued?Clinical Infectious Diseases, 1999
- INCIDENCE OF Pneumocystis carinii PNEUMONIA AFTER RENAL TRANSPLANTATIONTransplantation, 1996
- Rejection Treatment and Cytomegalovirus Infection as Risk Factors for Pneumocystis carinii Pneumonia in Renal Transplant RecipientsClinical Infectious Diseases, 1996
- PREVENTION OF Pneumocystis carinii PNEUMONIA IN CARDIAC TRANSPLANT RECIPIENTS BY TRIMETHOPRIM SULFAMETHOXAZOLETransplantation, 1993
- Risk of Infectious Complications in Patients Taking GlucocorticosteroidsClinical Infectious Diseases, 1989